The gene-guided dosing strategy of warfarin generally leads to over-dose in patients at doses lower than 2 mg/kg, and only 50% of individual variability in daily stable doses can be explained. In this study, we developed a novel population pharmacokinetic (PK) model based on a warfarin dose algorithm for Han Chinese patients with valve replacement for improving the dose prediction accuracy, especially in patients with low doses. The individual pharmacokinetic (PK) parameter -apparent clearance of Sand R-warfarin (CLs) was obtained after establishing and validating the population PK model from 296 recruited patients with valve replacement. Then, the individual estimation of CLs, VKORC1 genotypes, the steady-state international normalized ratio (INR) values and age were used to describe the maintenance doses by multiple linear regression for 144 steady-state patients. The newly established dosing algorithm was then validated in an independent group of 42 patients and was compared with other dosing algorithms for the accuracy and precision of prediction. The final regression model developed was as follows: Dose=-0.023×AGE+1.834×VKORC1+0.952×INR+2.156×CLs (the target INR value ranges from 1.8 to 2.5). The validation of the algorithm in another group of 42 patients showed that the individual variation rate (71.6%) was higher than in the gene-guided dosing models. The over-estimation rate in patients with low doses (<2 mg/kg) was lower than the other dosing methods. This novel dosing algorithm based on a population PK model improves the predictive performance of the maintenance dose of warfarin, especially for low dose (<2 mg/d) patients.
Introduction
Warfarin is still regarded as the cornerstone of the anticoagulation regimen used for patients after valve replacement and with non-valvular atrial fibrillation. However, its optimal effectiveness and safety is limited by significant individual variability in dose response and the narrow therapeutic index, especially for patients who are warfarin sensitive (≤1.5 mg/d) [1] . Even with frequent INR monitoring, the percentage of patients within the therapeutic range of warfarin is generally <60% in usual care settings [2] . Therefore, an individual dosage adjustment of warfarin is necessary. For many of the newly developed dose prediction models of warfarin, only approximately 40%-60% of individual variability of daily stable doses can be accounted for by basic demographic and genetic information [3] [4] [5] [6] [7] . Additionally, the models of Ohno, Wen and Huang et al tend to overestimate the low dose of warfarin (≤3 mg/d), and the overestimated rates [(estimate dose-actual dose)/actual dose×100%] are 57%, 48%, and
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Development of a novel individualized warfarin dose algorithm based on a population pharmacokinetic model with improved prediction accuracy for Chinese patients after heart valve replacement www.chinaphar.com Zhu YB et al Acta Pharmacologica Sinica 41%, respectively [4] [5] [6] . Recently, the study of population pharmacokinetic/pharmacodynamics (PPK/PPD) has offered a new opportunity for individualized treatment with warfarin. By applying a PPK/ PPD model, the algorithm established by Sasaki et al [8] based on CYP2C9, VKORC1 and clinical factors is more effective than other pharmacogenomics (PG) algorithms in predicting the stable dose of warfarin in 49 Japanese patients, with a small prediction bias (mean prediction error, ME=0.01 mg) and a high degree of precision (root mean squared error, RMSE=0.44 mg), giving a strong correlation between actual and predicted maintenance doses (r 2 =0.944). In Anna-Karin Hamberg's study, an adult PK/PD model for warfarin was adjusted for children using allometric scaling methods and increased the prediction proportion of children within ±20% of the actual dose to 70% [9] . In our earlier research, a warfarin dose algorithm based on pharmacogenetics and clinical factors has been obtained, which can explain 51.7% of the dose variability of warfarin and can predict doses ranging from 1.875 mg to 3.125 mg per day accurately [10] . However, Chinese patients are more sensitive to warfarin anticoagulation and are routinely administered lowintensity warfarin anticoagulation (target INR lower than 2 to 3). Therefore, in this study, we aimed to develop a population PK model-based dose algorithm to explain the dose variability of warfarin, especially for patients with low doses. Because S-warfarin is 3-to 5-fold more potent than R-warfarin [11] , the plasma concentration of S-and R-warfarin in patients was studied separately to better illustrate the dose algorithm. Based on this model, the individual PK (apparent clearance of S-warfarin, CLs) parameters can be estimated. The maintenance dose of warfarin was described by multiple linear regression using the population PK parameters of S-warfarin, CLs, the values of INR and other clinical and genetic factors.
Materials and methods

Patient information and treatment
From December 2013 to August 2014, 338 Han Chinese patients who required long-term treatment with warfarin after valve replacement, with a target INR between 1.8 and 2.5, were recruited randomly from the Cardiovascular Clinic of the Nanjing First Hospital, Nanjing Medical University, China. For the 338 patients, 296 were used for establishing (cohort 1, n=242) and externally validating (cohort 2, n=54) the population PK model. The basic information of these 296 patients is summarized in Table 1 . The patients were excluded if they had [10] : intracranial hemorrhage, hemorrhage of the digestive tract and urogenital system in the past 6 months, severe liver and kidney diseases, long-term use of non-steroidal antiinflammatory drugs, antiplatelet and anticoagulant drugs except for warfarin, and thrombolytic drugs, pregnancy and malignant tumors, definite or suspected blood system diseases (except for mild, moderate anemia), platelet deficiency (platelet <100×10 9 /L), and known non-compliance with warfarin therapy or prescribed INR monitoring. The relevant information of these patients was available.
Two to three days after the operation, warfarin was administered at 8:00 PM every day. The dosing regimen was adjusted according to changes of the INR values. The follow-up visits of the patients lasted 6-12 months after discharge, and the steady state INR and maintenance doses were recorded.
The study was approved by the Ethics Committee of Nanjing Medical University. All of the volunteers signed a written informed consent form according to the principles of the Declaration of Helsinki.
The warfarin plasma concentration measurement and genotyp ing The warfarin sampling time was 10 h after the previous administration, and the sampling interval varied from 24 h to 264 h. At least 1 to 3 samples were collected from each of the 296 patients from the total of 338 patients in this manner within 14 d after the heart valve replacement operation. The concentrations of R-warfarin and S-warfarin were then measured by high-performance liquid chromatography (HPLC). Separation was performed on the Chiralomix SA analytical column (4.6 mm×250 mm, 5 μm, Sepax Technologies, Inc, Delaware, USA) with the column temperature at 20 °C, and the mobile phase consisted of 20% ethanol:80% hexane with a flow rate of 1.0 mL/min. The detection wavelength was set at 308 nm. The detection range of the R-and S-warfarin concentration was 50-2000 ng/mL.
The sequencing of the fluorescence of the ligase detection reaction (LDR) that was applied for the genotyping of CYP2C9 and VKORC1-1639 of the 338 patients was performed on an ABI PRISM 3730 DNA sequencer (Applied Biosystems, Foster City, CA, USA). All SNPs were assessed to ensure that they were in Hardy-Weinberg equilibrium. More details were provided in our previous study [10] .
The Pharmacokinetic modeling For 242 of the 296 patients, a total of 508 R-warfarin and 506 S-warfarin plasma concentrations were obtained and used for developing the population PK models. A one-compartment model with first-order absorption and first-order elimination was used for the PK modeling of R-and S-warfarin using NONMEN software (version 6.0) [12] [13] [14] [15] [16] [17] . S-PLUS 6.1 (Insightful Corporation, Seattle, WA, USA) was used for model evaluation by the bootstrap method. The clearance (CL) and apparent distribution volume (V) were parameterized (in Equations 1-3) [11] .
where Y was the observed plasma concentration, θ CL and θ V were the population means for CL and V, respectively, F was the population-based predicted plasma concentration, η CL and η V were the inter-individual variability of CL and V, respectively, and EPS (1) was the residual error variability of Y.
The pharmacokinetic parameters CL and V and their interindividual variation-η (η CL , η V ) of the 242 patients were then calculated by the base PK models. The relationship between η (η CL , η V ) and the categorical covariates (gender, smoking, drinking history, number of the replaced valves, hypertension, diabetes, atrial fibrillation, thrombus in the atrium sinistrum, deep vein and pulmonary embolism history, concomitant medications, and the CYP2C9 and VKORC1-1639 genotypes) and continuous covariates (age, height, body surface area, body mass index, white blood cell, hemoglobin, platelet, total protein, and albumin) were analyzed by ANOVA and Spearman analysis, respectively. Each candidate covariate was screened in turn by adding it into the base model. The potential covariates were included nonlinearly into the corresponding PK parameter models in forward inclusion and only those that made the objective function value (OFV) decrease more than 3.84 (P<0.05, df=1) were retained. Then, the retained covariates were removed from the models in backward elimination and only those that made the OFV increase more than 6.63 (P<0.01, df=1) were finally retained.
Model validation
The population averages of the pharmacokinetic parameters CL and V (θ CL and θ V ) were fixed by the FIXED statements in NONMEN control documents after establishing the final PK models for the 242 patients. Then, the 85 R-warfarin and 82 S-warfarin plasma concentrations obtained from the remaining 54 patients (cohort 2) were iterated by NONMEN and the predictive plasma concentrations of warfarin were obtained. The prediction result of the 54 patients (cohort 2) was then compared with that of the 242 patients (cohort 1) to evaluate the accuracy and precision of external validation of the final PopPK models, by comparing WR (population weight residual), AWR (population absolute weight residual), IWR (individual weight residual) and IAWR (individual absolute weight residual) and the scatter-plots of DV-PRED (observed concentration vs population predicted concentration) and DV-IPRED (observed concentration vs individual predicted (7) where CP ij was the jth observed concentration of the ith patient, PRED ij was the jth population prediction concentration of the ith patient, and IPRED ij was the jth individual prediction concentration of the ith patient calculated by the POSTHOC method.
Establishment of the maintenance dosing algorithm After 6-12 months of follow-up visits for the 296 patients, a total of 186 patients reached a steady-state of anticoagulation with available steady state INR values and maintenance doses. Among the 186 patients, 144 were randomly selected as "cohort 3" for developing the dose equation, and the remaining 42 patients constituted "cohort 4" for validation of the dose equation. The individual PK parameter for the 144 steadystate patients (apparent clearance of S-warfarin, CLs) could be estimated by Bayesian forecasting based on the population PK model developed in the 242 patients [18] . Then, a multiple linear regression analysis was performed to evaluate the association between the individual PK parameter-CLs, the observed individual INR value, age and the actual maintenance dose with SPSS19.0 software.
Validation of the dosing algorithm and comparison with other dosing algorithms
The newly established dosing algorithm was then validated in another independent group of 42 patients, and the correlation analysis was performed between the predicted and the actual dose. Then, the mean prediction error (ME) and root mean squared error (RSME) of these 42 patients obtained by the new dosing algorithms were used to evaluate and compare the accuracy and precision with other dosing algorithms. A lower ME represents a smaller bias between the predicted and the actual dose. A lower RMSE represents a higher degree of prediction precision. The formulas of ME and RMSE were listed as follows:
where N was the number of subjects, and V pred,j and V obs,j were the jth predicted and observed value, respectively, such as maintenance dose, INR, Cps, etc.
Results
Patient information
In total, 338 patients were recruited in this study, of which 296 patients were used for the PopPK modeling and algorithm establishment, and the remaining 42 patients were used for external validation. The basic information of the 296 patients was presented in Table 1 , of which 242 patients were randomly selected as "cohort 1" for developing the PopPK model, and 54 of them constituted "cohort 2" for external validation of the PopPK model. The Chi-square test or the two-sample t-test was performed to compare the differences of the basic information for the 2 cohorts.
The population pharmacokinetic modeling
The plasma concentration of R-and S-warfarin could both be successfully fitted using the one-compartment model (ADVAN2 TRANS2). The significant covariates by correlation analysis were introduced into the models in certain forms. Their reservation in the models was based on the change of OFV and the inter-and intra-individual variation of the PK parameters. The final PK models with 242 patients were obtained by the forward stepwise inclusion and backward stepwise elimination methods. The final PK models and the population PK parameters of the final PK models are shown in Table 2 and Table 3 .
The goodness of fit diagnostic plots for the final population TVCL was the population value of clearance; TVV was the population value of distribution volume; GEND stands for gender, when the object is male, GEND is 0, when the object is female, GEND is 1; BSA stand for the body surface area; CYP2C9: when it is the genotype of CYP2C9*1/*1, then CYP2C9 is 0, when it is the genotype of CYP2C9*1/*3, then CYP2C9 is 1; θ CL and θ V were the population averages for CL and V, respectively; θ CYP2C9 stands for the effect of CYP2C9*1/*3 (% reduction) on the apparent clearance of S-warfarin; θ BSA stands for the effect of body surface area (% change/m 2 )
on the apparent clearance of S-warfarin; θ GEND stands for the effect of the gender of female on the (% change) on the apparent distribution volume of R-warfarin. P j 0 and P j was the jth predicted and actual PK parameter respectively, η Pj was the inter-individual variation of P j . C ij 0 and C ij was the jth predicted and actual plasma concentration of the ith patient respectively, ε ij was the intra-individual variation of C ij . 
Validation of the final population pharmacokinetic model
The population and the individual values of R-and S-warfarin plasma concentrations were estimated in cohort 1 (242 patients) and cohort 2 (54 patients), respectively. The scatterplots are shown in Figure 3 .
The result showed that the correlation between DV (dependent variable, the observed concentrations in this study) and IPRED (the individual predictive value) by Bayesian forecast- OFV stands for the object function value; CL is the apparent clearance; V is the apparent distribution volume; θ CL and θ v were the population averages for CL and V, respectively; θ CYP2C9 stands for the effect of CYP2C9*1/*3 (% reduction) on the apparent clearance of S-warfarin; θ BSA stands for the effect of body surface area (% change/m 2 ) on the apparent clearance of S-warfarin; θ GEND stands for the effect of the gender of female on the (% change) on the apparent distribution volume of R-warfarin. ω CL , ω v stand for the variance of the inter-individual variation of CL and V, respectively; σ stands for the variance of the intra-individual variation of plasma concentrations. CV: Coefficient of variation, CV=SD/Mean*100%.
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Acta Pharmacologica Sinica ing was stronger than that of PRED (the population predictive value). The points in the DV-IPRED scatter-plots were distributed uniformly around the diagonal line, with a similar slope and intercept of the regression line, indicating a good prediction effect of the final PK models for the R-and S-warfarin concentration of the patients in cohort 1 and cohort 2. Meanwhile, the WR, IWR, AWR, and IAWR of each observed concentration and their median and average values in cohort 1 were calculated, which were compared with those in cohort 2, to evaluate the prediction accuracy of the external validation ( Table 4 ).
The result showed that there was no significant difference of IWR and IAWR between the two cohorts, and their mean and median values were similar, indicating the similar prediction accuracy between the two cohorts.
Building the maintenance dosing algorithm During the 6-12 month follow-up visits for the 296 discharged patients, the INR values of 186 patients (shown in Table 1 ) reached steady state (cohort 3 for developing the dose equation, n=144; cohort 4 for external validation, n=42. The Chisquare test or the two-sample t-test was performed to compare the differences of the basic information for the 2 cohorts). The individual prediction of CLs (the clearance of S-warfarin) and CLr (the clearance of R-warfarin) for the 144 patients in cohort 3 could be obtained by Bayesian forecasting.
Although the plasma concentrations of R-warfarin were almost as much as 2-fold of S-warfarin, the CLr did not have a correlation relationship with the steady-state dose; therefore, CLr was not included in the final dose algorithm. With respect to S-warfarin, in this study, unlike the research of Hamberg [12] and Lane [13] , gender, age and weight were not found to have an influence on the clearance of S-warfarin and were not included in the parameter estimates of CLs. As a result, they may not be entered into the final dose prediction formula. However, for the other dose equations [4] [5] [6] [7] [8] , gender, age and weight were important factors that affected the dosage of warfarin, so these three factors should be included in the dose prediction formula. In the end, CLs, VKORC1 genotypes, the steady-state INR values, gender, age and weight were all used for the multivariate regression. The final multiple regression model, selected by means of the stepwise backward elimination procedure, is summarized in 
Validation of the dosing model and comparison with other dosing algorithms
The result of external validation of the algorithm in the independent group of 42 patients is shown in Figure 4 , with a high correlation coefficient (R 2 =0.716) between the predicted and the actual maintenance dose. The result also revealed that the equation tended to overestimate for doses less than 2 mg and underestimate for doses more than 4 mg. The comparison of the predictive performance of the current and other dosing methods for the 42 patients is shown in Table 6 . The result showed that the ME and RSME of our prediction algorithm were smaller than almost all of the other 4 models. Although our equation tended to overestimate for doses lower than 2 mg/d (Figure 4) , the results of subgroup analysis of the 18 patients (<2 mg/d) in cohort 4 showed that the prediction accuracy and precision of our equation were still better than the other 5 dose formulas (Table 7 ). 
Discussion
Although the therapeutic index of warfarin is narrow, the research of Sjögren [19] in 77 423 patients recently showed that as long as the proportion of time in the therapeutic range was high, warfarin will continue to be a valid treatment option in the era of newer oral anticoagulants. In this study, we established a new dosing prediction model, a population PK-PD model, by using the individual PK parameter (CLs) forecasted by the Bayesian method, the INR value of the steady state, and the age of the patients. The new dosing model gave higher individual variation rates (71.6%) than the general geneguided dosing models (50%) [7, 20] . The basic R-and S-warfarin PK model could be fitted better by a one-compartment model compared with the two-compartment model, with a decrease in the relative standard error (SE%) of clearance from 29.6% to 4.1%, which was similar to the study of Hamberg [12] and Lane [13] . This was the first time that the population PK models of R-and S-warfarin for the Han Chinese patients were developed. During the PK modeling of R-warfarin, no influence factor was found for CLr, and gender was identified as influencing the distribution volume, with the distribution volume of women 31.9% lower than men. However, in building the maintenance dosing algorithm, CLr and volume did not have a correlation relationship with the steady-state dose. As S-warfarin's PK parameter is better correlated with the steady-state dose compared to R-warfarin, we did not value the model predictive performance of the total warfarin.
The prediction accuracy of the plasma concentration of S-warfarin was improved by the Bayesian forecasting, with the correlation coefficient between the predicted and the actual value improving from 0.4506 to 0.8990 prior and post Bayesian inference. The mean value of individual CLs with Bayesian inference was 0.586 L/h, which was comparable with the previously reported clearance of S-warfarin (0.61 L/h) in a Chinese population [21] . Taking these results into consideration, the individual population PK parameters by Bayesian forecasting were acceptable for the maintenance dose prediction modeling of warfarin in Chinese patients.
Recent studies [22] have found that the algorithms from Caucasian and racially mixed populations tended to perform better in the higher dose group (≥4.5 mg/d), and algorithms from Asian populations performed better in the intermediate dose group (1.5-4.5 mg/d). None of the algorithms performed well in the lower dose group (≤1.5 mg/d). In our research, the prediction precision of our model for the low-dose (<2 mg/d) patients was improved, with the value of ME and RMSE lower than the other 4 gene-guided algorithms [4, 6, 7, 17] in the validation group. In this research, the prediction accuracy and precision (predicted dose-actual dose)/actual dose× 100%) for the 18 patients with low dose (<2 mg/d) in cohort 4 (n=42) was better than the other 4 models (ME: -0.03 mg vs 1.74 mg, 0.03 mg, 1.16 mg, 0.74 mg; RMSE: 0.31 mg vs 1.87 mg, 0.32 mg, 1.23 mg, 0.86 mg). By comparing the difference of the values of CLs, INR and age of the 4 models (the Chisquare test or the two-sample nonparametric Mann Whitney U test were performed to compare the differences of the basic information for these 2 groups), there was a significant difference in age (56.11±9.98 years vs 48.71±11.54 years, P=0.044) and VKORC1-1173 (P=0.005) between the two groups. This result indicated that age and VKORC1-1173 genotypes may be important potential factors that improve the prediction rate for the patients with low dose (<2 mg/d). However, CYP2C9, the primary enzyme of warfarin metabolism, which is a commonly accepted factor in most reported models about warfarin dose prediction, was included in the equation CLs=θ CL ×(1-CYP2C9×θ CYP2C9 ; for CYP2C9: when it is the genotype of CYP2C9*1/*1, then CYP2C9 is 0; when it is the genotype of CYP2C9*1/*3, then CYP2C9 is 1).
The result of the multiple linear regression modeling showed that the correlation coefficient between the prediction dose and actual dose was 0.6658, indicating that there are still "unknown factors" determining individual maintenance doses. In addition, the measurements of the drug concentration and INR levels might require extra costs and a delay until the therapeutic dose can be estimated, but it would be worth it for the low dose Chinese patients with a high risk of bleeding.
In conclusion, we established a new algorithm based on the PK/PD model, with a high accuracy of warfarin dose prediction for Han Chinese patients, especially for low dose (<2 mg/d) patients. [17] 1.74
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